OTC Markets OTCQB - Delayed Quote USD

Zelira Therapeutics Limited (ZLDAF)

Compare
0.3334
0.0000
(0.00%)
At close: January 29 at 3:00:00 PM EST
Currency in AUD All numbers in thousands
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
94.9520
94.9520
301.1210
1,540.6240
432.5680
Cost of Revenue
84.6680
84.6680
362.5600
939.0540
228.2220
Gross Profit
10.2840
10.2840
-61.4390
601.5700
204.3460
Operating Expense
5,948.5140
5,948.5140
7,201.6910
14,247.0270
10,195.5230
Operating Income
-5,938.2300
-5,938.2300
-7,263.1300
-13,645.4570
-9,991.1770
Net Non Operating Interest Income Expense
-738.9630
-738.9630
-76.5270
-43.2530
-41.9040
Other Income Expense
-30,062.5660
-30,062.5660
1,070.9250
1,275.1920
1,484.0020
Pretax Income
-36,739.7590
-36,739.7590
-6,268.7320
-12,413.5180
-8,549.0790
Net Income Common Stockholders
-36,568.9040
-36,568.9040
-5,573.0070
-11,945.3030
-8,549.0790
Basic EPS
-3.24
-3.22
-0.55
-1.54
-1.28
Diluted EPS
-3.24
-3.22
-0.55
-1.54
-1.28
Basic Average Shares
10,953.2720
11,347.1550
10,068.2530
8,042.4320
6,632.6960
Diluted Average Shares
10,953.2720
11,347.1550
10,068.2530
8,042.4320
6,632.6960
Net Income from Continuing & Discontinued Operation
-36,568.9040
-36,568.9040
-5,573.0070
-11,945.3030
-8,549.0790
Normalized Income
-5,577.6030
-5,577.6030
-5,306.4920
-11,945.3030
-8,549.0790
Interest Income
0.3090
0.3090
0.1340
10.5950
0.7230
Interest Expense
739.2720
739.2720
76.6610
53.8480
42.6270
Net Interest Income
-738.9630
-738.9630
-76.5270
-43.2530
-41.9040
EBIT
-36,000.4870
-36,000.4870
-6,192.0710
-12,359.6700
-8,506.4520
EBITDA
-35,521.4490
-35,521.4490
-5,646.8470
-11,771.1270
-8,032.1970
Reconciled Cost of Revenue
84.6680
84.6680
362.5600
939.0540
228.2220
Reconciled Depreciation
479.0380
479.0380
545.2240
588.5430
474.2550
Net Income from Continuing Operation Net Minority Interest
-36,568.9040
-36,568.9040
-5,573.0070
-11,945.3030
-8,549.0790
Total Unusual Items Excluding Goodwill
-30,991.3010
-30,991.3010
-266.5150
--
--
Total Unusual Items
-30,991.3010
-30,991.3010
-266.5150
--
--
Normalized EBITDA
-4,530.1480
-4,530.1480
-5,380.3320
-11,771.1270
-8,032.1970
6/30/2021 - 3/7/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade